310 related articles for article (PubMed ID: 28502091)
1. Increased Pretransplant Frequency of CD28
Cortes-Cerisuelo M; Laurie SJ; Mathews DV; Winterberg PD; Larsen CP; Adams AB; Ford ML
Am J Transplant; 2017 Sep; 17(9):2350-2362. PubMed ID: 28502091
[TBL] [Abstract][Full Text] [Related]
2. Belatacept-Resistant Rejection Is Associated With CD28
Mathews DV; Wakwe WC; Kim SC; Lowe MC; Breeden C; Roberts ME; Farris AB; Strobert EA; Jenkins JB; Larsen CP; Ford ML; Townsend R; Adams AB
Am J Transplant; 2017 Sep; 17(9):2285-2299. PubMed ID: 28502128
[TBL] [Abstract][Full Text] [Related]
3. Postdepletion Lymphocyte Reconstitution During Belatacept and Rapamycin Treatment in Kidney Transplant Recipients.
Xu H; Samy KP; Guasch A; Mead SI; Ghali A; Mehta A; Stempora L; Kirk AD
Am J Transplant; 2016 Feb; 16(2):550-64. PubMed ID: 26436448
[TBL] [Abstract][Full Text] [Related]
4. mTOR Inhibitor Therapy Diminishes Circulating CD8+ CD28- Effector Memory T Cells and Improves Allograft Inflammation in Belatacept-refractory Renal Allograft Rejection.
Castro-Rojas CM; Godarova A; Shi T; Hummel SA; Shields A; Tremblay S; Alloway RR; Jordan MB; Woodle ES; Hildeman DA
Transplantation; 2020 May; 104(5):1058-1069. PubMed ID: 31415033
[TBL] [Abstract][Full Text] [Related]
5. Belatacept Combined With Transient Calcineurin Inhibitor Therapy Prevents Rejection and Promotes Improved Long-Term Renal Allograft Function.
Adams AB; Goldstein J; Garrett C; Zhang R; Patzer RE; Newell KA; Turgeon NA; Chami AS; Guasch A; Kirk AD; Pastan SO; Pearson TC; Larsen CP
Am J Transplant; 2017 Nov; 17(11):2922-2936. PubMed ID: 28544101
[TBL] [Abstract][Full Text] [Related]
6. TIGIT regulates apoptosis of risky memory T cell subsets implicated in belatacept-resistant rejection.
Sun H; Hartigan CR; Chen CW; Sun Y; Tariq M; Robertson JM; Krummey SM; Mehta AK; Ford ML
Am J Transplant; 2021 Oct; 21(10):3256-3267. PubMed ID: 33756063
[TBL] [Abstract][Full Text] [Related]
7. ASP2409, A Next-Generation CTLA4-Ig, Versus Belatacept in Renal Allograft Survival in Cynomolgus Monkeys.
Song L; Ma A; Dun H; Hu Y; Fujii Y; Kinugasa F; Oshima S; Higashi Y; Daloze P; Chen H
Am J Transplant; 2017 Mar; 17(3):635-645. PubMed ID: 27598231
[TBL] [Abstract][Full Text] [Related]
8. Selective Targeting of High-Affinity LFA-1 Does Not Augment Costimulation Blockade in a Nonhuman Primate Renal Transplantation Model.
Samy KP; Anderson DJ; Lo DJ; Mulvihill MS; Song M; Farris AB; Parker BS; MacDonald AL; Lu C; Springer TA; Kachlany SC; Reimann KA; How T; Leopardi FV; Franke KS; Williams KD; Collins BH; Kirk AD
Am J Transplant; 2017 May; 17(5):1193-1203. PubMed ID: 27888551
[TBL] [Abstract][Full Text] [Related]
9. Secondary lymphoid tissue and costimulation-blockade resistant rejection: A nonhuman primate renal transplant study.
Mulvihill MS; Samy KP; Gao QA; Schmitz R; Davis RP; Ezekian B; Leopardi F; Song M; How T; Williams K; Barbas A; Collins B; Kirk AD
Am J Transplant; 2019 Aug; 19(8):2350-2357. PubMed ID: 30891931
[TBL] [Abstract][Full Text] [Related]
10. High CTLA-4 expression on Th17 cells results in increased sensitivity to CTLA-4 coinhibition and resistance to belatacept.
Krummey SM; Cheeseman JA; Conger JA; Jang PS; Mehta AK; Kirk AD; Larsen CP; Ford ML
Am J Transplant; 2014 Mar; 14(3):607-14. PubMed ID: 24730049
[TBL] [Abstract][Full Text] [Related]
11. CD57(+) CD4 T Cells Underlie Belatacept-Resistant Allograft Rejection.
Espinosa J; Herr F; Tharp G; Bosinger S; Song M; Farris AB; George R; Cheeseman J; Stempora L; Townsend R; Durrbach A; Kirk AD
Am J Transplant; 2016 Apr; 16(4):1102-12. PubMed ID: 26603381
[TBL] [Abstract][Full Text] [Related]
12. Anti-CD28 Antibody and Belatacept Exert Differential Effects on Mechanisms of Renal Allograft Rejection.
Ville S; Poirier N; Branchereau J; Charpy V; Pengam S; Nerriere-Daguin V; Le Bas-Bernardet S; Coulon F; Mary C; Chenouard A; Hervouet J; Minault D; Nedellec S; Renaudin K; Vanhove B; Blancho G
J Am Soc Nephrol; 2016 Dec; 27(12):3577-3588. PubMed ID: 27160407
[TBL] [Abstract][Full Text] [Related]
13. Belatacept in renal transplant recipient with mild immunologic risk factor: A pilot prospective study (BELACOR).
Leibler C; Matignon M; Moktefi A; Samson C; Zarour A; Malard S; Boutin E; Pilon C; Salomon L; Natella PA; Durrbach A; Robert T; Canoui-Poitrine F; Grimbert P
Am J Transplant; 2019 Mar; 19(3):894-906. PubMed ID: 30582270
[TBL] [Abstract][Full Text] [Related]
14. Effect of an Early Switch to Belatacept Among Calcineurin Inhibitor-Intolerant Graft Recipients of Kidneys From Extended-Criteria Donors.
Le Meur Y; Aulagnon F; Bertrand D; Heng AE; Lavaud S; Caillard S; Longuet H; Sberro-Soussan R; Doucet L; Grall A; Legendre C
Am J Transplant; 2016 Jul; 16(7):2181-6. PubMed ID: 26718625
[TBL] [Abstract][Full Text] [Related]
15. Belatacept in kidney transplantation.
Wojciechowski D; Vincenti F
Curr Opin Organ Transplant; 2012 Dec; 17(6):640-7. PubMed ID: 23044530
[TBL] [Abstract][Full Text] [Related]
16. IL-7 receptor heterogeneity as a mechanism for repertoire change during postdepletional homeostatic proliferation and its relation to costimulation blockade-resistant rejection.
Xu H; Bendersky VA; Brennan TV; Espinosa JR; Kirk AD
Am J Transplant; 2018 Mar; 18(3):720-730. PubMed ID: 29136317
[TBL] [Abstract][Full Text] [Related]
17. Abatacept as rescue immunosuppression after calcineurin inhibitor treatment failure in renal transplantation.
Badell IR; Karadkhele GM; Vasanth P; Farris AB; Robertson JM; Larsen CP
Am J Transplant; 2019 Aug; 19(8):2342-2349. PubMed ID: 30768841
[TBL] [Abstract][Full Text] [Related]
18. Cytomegalovirus-Associated CD4(+) CD28(null) Cells in NKG2D-Dependent Glomerular Endothelial Injury and Kidney Allograft Dysfunction.
Shabir S; Smith H; Kaul B; Pachnio A; Jham S; Kuravi S; Ball S; Chand S; Moss P; Harper L; Borrows R
Am J Transplant; 2016 Apr; 16(4):1113-28. PubMed ID: 26603521
[TBL] [Abstract][Full Text] [Related]
19. Down-Regulation of Surface CD28 under Belatacept Treatment: An Escape Mechanism for Antigen-Reactive T-Cells.
de Graav GN; Hesselink DA; Dieterich M; Kraaijeveld R; Weimar W; Baan CC
PLoS One; 2016; 11(2):e0148604. PubMed ID: 26919152
[TBL] [Abstract][Full Text] [Related]
20. Alloreactive CD154-expressing T-cell subsets with differential sensitivity to the immunosuppressant, belatacept: potential targets of novel belatacept-based regimens.
Ashokkumar C; Ganguly B; Townsend R; White J; Levy S; Moritz M; Mazariegos G; Sun Q; Sindhi R
Sci Rep; 2015 Oct; 5():15218. PubMed ID: 26472085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
